Filing Flows › Kymera Therapeutics (KYMR) › Q2 2026
Kymera Therapeutics (KYMR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Kymera Therapeutics (KYMR) reported revenue of $65.0M for the second quarter 2026 (Q2 2026), +466% from a year earlier and +89% from the quarter before. Operating margin was -116.3%, net loss $61.2M (94.2% of revenue).
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $65.0M | +89% | +466% |
| Operating profit | −$75.6M | — | — |
| Net earnings | −$61.2M | — | — |
| Operating cash flow | −$54.1M | — | — |
What changed
Revenue was $65.0M in Q2 2026, up 466% year over year and up 89% from the previous quarter.
Operating costs exceeded revenue by $75.6M, an operating margin of -116.3%. Total costs grew 46% against revenue growth of 466%. The quarter ended with a net loss of $61.2M, narrower than the previous quarter's $69.2M loss. Non-operating items added $14.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$54.1M. Non-cash charges added back $2.0M of depreciation and amortization and $18.9M of share-based compensation. Working capital and other items used $13.8M. Capital expenditures of $473K exceeded it, leaving free cash flow of −$54.5M.
Questions
What was Kymera Therapeutics' revenue in the second quarter 2026?
Kymera Therapeutics (KYMR) reported revenue of $65.0M for the second quarter 2026 (Q2 2026), +466% from a year earlier and +89% from the quarter before.
Was Kymera Therapeutics profitable in the second quarter 2026?
Operating loss was $75.6M (-116.3% of revenue) and net loss $61.2M.